



## Curriculum Vitae

Personal information **Jana Mazelova**

### Work experience

1. Employer: State Institute for Drug Control
  - Start date: 042011
  - End date:
  - Position: Assessor
  - Activities: Evaluation of clinical documentation accompanying the reimbursement applications with focus on hemato\_oncology and oncology (clinical efficacy and safety)
  - Country: Czechia
2. Employer: University of New Mexico
  - Start date: 012004
  - End date: 062009
  - Position: Postdoctoral Fellow
  - Activities: Research in the field of cell pathology, ophthalmology
  - Country: United States
3. Employer: Thomayer University Hospital, Prague
  - Start date: 2002
  - End date: 2003
  - Position: Physician, department of Rheumatology
  - Activities:
  - Country: Czechia

### Education and training

1. Subject: Charles University, Prague
  - Start date: 091999
  - End date: 122003
  - Qualification: Ph.D. – neuroscience
  - Organisation: Auditory neuroscience \_ auditory function in presbycusis
  - Country: Czechia
2. Subject: Second Medical Faculty, Charles University
  - Start date: 091987
  - End date: 041995
  - Qualification: M.D. (Doctoral degree in general medicine)
  - Organisation:
  - Country: Czechia

### Additional information

#### Publications

Popelar J, Mazelová J, Syka J. Effects of electrical stimulation of the inferior colliculus on 2f1\_f2 distortion product otoacoustic emissions in anesthetized guinea pigs. *Hear Res.* 2002 Aug;170(1\_2):116\_26. doi: 10.1016/s0378\_5955(02)00397\_0. Hear Res. 2002. PMID: 12208546 Syka J, Rybalko N, Mazelová J, Druga R. *Hear Res.* 2002 Oct;172(1\_2):151\_9. doi: 10.1016/s0378\_5955(02)00578\_6. Hear Res. 2002. PMID: 12361878. Gap detection threshold in the rat before and after auditory cortex ablation. Mazelová J, Popelar J, Syka J. *Auditory function in presbycusis: peripheral vs. central changes.* *Exp Gerontol.* 2003 Jan\_Feb;38(1\_2):87\_94. doi: 10.1016/s0531\_5565(02)00155\_9. *Exp Gerontol.* 2003. PMID: 12543265 Popelar J, Groh D, Mazelova J, Syka J. Cochlear function in young and adult Fischer 344 rats. *Hear Res.* 2003 Dec;186(1\_2):75\_84. doi: 10.1016/s0378\_5955(03)00329\_0. *Hear Res.* 2003. PMID: 14644461 Deretic D, Mazelova J. Assay for in vitro budding of ciliary\_targeted rhodopsin transport carriers. *Methods Cell Biol.* 2009;94:241\_57. doi: 10.1016/S0091\_679X(08)94012\_7. *Epub* 2009 Dec 23. *Methods Cell Biol.* 2009. PMID: 20362094 Mazelova J, Astuto\_Gribble L, Inoue H, Tam BM, Schonteich E, Prekeris R, Moritz OL, Randazzo PA, Deretic D. Ciliary targeting motif VxPx directs assembly of a trafficking module through Arf4. *EMBO J.* 2009 Feb 4;28(3):183\_92. doi: 10.1038/emboj.2008.267. *Epub* 2009 Jan 15. *EMBO J.* 2009. PMID: 19153612 Mazelova J, Ransom N, Astuto\_Gribble L, Wilson MC, Deretic D. Syntaxin 3 and SNAP\_25 pairing, regulated by omega\_3 docosahexaenoic acid, controls the delivery of rhodopsin for the biogenesis of cilia\_derived sensory organelles, the rod outer segments. *J Cell Sci.* 2009 Jun 15;122(Pt 12):2003\_13. doi: 10.1242/jcs.039982. *Epub* 2009 May 19. *J Cell Sci.* 2009. PMID: 19454479 Wang J, Morita Y, Mazelova J, Deretic D. The Arf GAP ASAP1 provides a platform to regulate Arf4\_ and Rab11\_Rab8\_ mediated ciliary receptor targeting. *EMBO J.* 2012 Oct 17;31(20):4057\_71. doi: 10.1038/emboj.2012.253. *Epub* 2012 Sep 14. *EMBO J.* 2012. PMID: 22983554 Mazelova J, Slaby J. Reimbursed Pharmacotherapy of Metastatic Clear Cell Kidney Cancer (MCCKC) in the Czech Republic. *Value Health.* 2014 Nov;17(7):A658. doi: 10.1016/j.jval.2014.08.2408. *Epub* 2014 Oct 26. *Value Health.* 2014. PMID: 27202388 Vostalová L, Mazelová J, Samek J, Vocolka M. Health Technology Assessment in Evaluation of Pharmaceuticals in the Czech Republic. *Int J Technol Assess Health Care.* 2017 Jan;33(3):339\_344. doi: 10.1017/S0266462317000204. *Epub* 2017 Apr 25. *Int J Technol Assess Health Care.* 2017. PMID: 28438231

#### Projects

#### Memberships

Member of COMP since January 2022.

Member of Subgroup for Joint CLinical Assessments EU HTA since May 2023.

Other Relevant Information